Approval · Notice of Compliance 7265 · 2005
VIDEX: Notice of Compliance 7265
Issued August 3, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7265
- Date
- August 3, 2005
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Dosing reduction when co-administered with tenofovir disoproxil fumarate
- Therapeutic class
- Antiretroviral agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIDEX | Not yet assigned | — |
| VIDEX EC | Not yet assigned | — |
Medicinal ingredients
- DIDANOSINE 25 MG per TAB
- DIDANOSINE 50 MG per TAB
- DIDANOSINE 100 MG per TAB
- DIDANOSINE 150 MG per TAB
- DIDANOSINE 2 G per BOTTL
- DIDANOSINE 4 G per BOTTL
- DIDANOSINE 100 MG per PCK
- DIDANOSINE 167 MG per PCK
- DIDANOSINE 250 MG per PCK
- DIDANOSINE 375 MG per PCK
- DIDANOSINE 125 MG per CAP
- DIDANOSINE 200 MG per CAP
- DIDANOSINE 250 MG per CAP
- DIDANOSINE 400 MG per CAP